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Second-Line Drug Susceptibilities of
Multidrug-Resistant Mycobacterium tuberculosis
Isolates in Aegean Region - Turkey*
Aim: The emergence of multidrug-resistant tuberculosis (MDR-TB) is increasing, and the standard shortcourse regimen used for the treatment of TB is likely to be ineffective against MDR-TB, leading to the need
for second-line drugs. In such situations, drug susceptibility testing is necessary to select an appropriate
treatment regimen. Unfortunately, there are few studies showing the pattern of the second-line drug
resistance in Turkey. We aimed to analyze the resistance to second-line anti-tuberculosis drugs of MDR strains
of Mycobacterium tuberculosis isolated from the Aegean region of Turkey.
Materials and Methods: In this study, drug susceptibility testing of 40 MDR-TB strains isolated from the
Aegean region of Turkey was performed using the BACTEC 460 TB radiometric system. Capreomycin,
ethionamide, kanamycin, amikacin, clofazimine and ofloxacin were tested in 1.25 µg/ml, 1.25 µg/ml, 5.0
µg/ml, 1.0 µg/ml, 0.5 µg/ml, and 2.0 µg/ml concentrations, respectively.
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Results: The results showed that 37.5% of the strains were resistant to ethionamide, 25% to capreomycin,
5% to kanamycin, amikacin and ofloxacin, and 2.5% to clofazimine. One (2.5%) of the 40 MDR-TB cases was
defined as extensively drug-resistant tuberculosis (XDR-TB).
Conclusions: The results of the study indicate that the high rates of resistance to ethionamide and
capreomycin may be a problem in the treatment of patients with MDR-TB; XDR-TB is not yet a serious
problem in our region.
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Ege Bölgesinde Çok ‹laca Dirençli Mycobacterium tuberculosis Izolatlar›n›n
‹kinci Kuﬂak Antitüberküloz ‹laçlara Duyarl›l›klar›
Amaç: Çok ilaca dirençli tüberküloz (MDR-TB) olgular›ndaki art›ﬂ ve standart tüberküloz tedavi rejiminin
MDR-TB olgular›n›n tedavisinde yetersiz kalmas› ikinci kuﬂak anti tüberküloz ilaçlar›n gereksinimine neden
olmaktad›r. Bu durumda do¤ru tedavi rejimine karar vermek için ilaç duyarl›l›k testleri gereklidir. Fakat ikinci
kuﬂak anti tüberküloz ilaçlar›n›n Türkiye’deki direnç paternini gösteren çok az çal›ﬂma vard›r. Biz Ege
bölgesinden izole edilen çok ilaca dirençli Mycobacterium tuberculosis suﬂlar›n›n ikinci kuﬂak antitüberküloz
ilaçlar›na direncini belirlemeyi amaçlad›k.
Yöntem ve Gereç: Bu çal›ﬂmada, BACTEC 460TB radyometrik sistem kullan›larak, Türkiye’nin Ege
bölgesinden soyutlanm›ﬂ 40 MDR-TB suﬂunun ilaç duyarl›l›k testi yap›ld›. Kapreomisin, etyonamid, kanamisin,
amikasin, klofazimin ve ofloksasin s›ras›yla 1.25 µg/ml, 1.25 µg/ml, 5.0 µg/ml, 1.0 µg/ml, 0.5 µg/ml ve 2.0
µg/ml konsantrasyonlar›nda test edildi.
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Bulgular: Sonuçlar 40 MDR-TB olgusunun etyonamide % 37.5, kapreomisin %25, kanamisin, amikasin ve
ofloksasine % 5 ve klofazimine ise % 2.5’inin dirençli oldu¤unu gösterdi. 40 MDR-TB olgusunun biri
geniﬂlemiﬂ ilaç dirençli tüberküloz (extensively drug-resistant tuberculosis: XDR-TB) olarak tan›mland›.
Sonuç: Bölgemizde etyonamide ve kapreomisine direnç oranlar›n›n yüksekli¤inin MDR-TB’li hastalar›n
tedavisinde sorun olabilece¤i ve XDR-TB’nin ise bölgemizde ﬂimdilik ciddi bir problem olmad›¤› görülmüﬂtür.
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Introduction
Although tremendous efforts to control tuberculosis
(TB) have been undertaken at global and national levels,
almost 2 million patients still die every year. Multidrugresistant (MDR)-TB, defined as resistance to at least
isoniazid and rifampin, has emerged as a worldwide threat
to TB control (1). MDR-TB treatment requires the use of
second-line drugs (SLDs) that are less effective, more
toxic, and costlier than first-line isoniazid and rifampin (2).
With the recent global resurgence of TB and concomitant
rise in MDR strains of Mycobacterium tuberculosis, there
is an increasing demand for determining the in-vitro
susceptibilities of clinical isolates to antimicrobial agents
other than the primary drugs (3). It was recommended
that whenever an isolate of M. tuberculosis is resistant to
rifampin or any two of the primary drugs, all SLDs should
also be tested (4). Treatment of patients with MDR-TB
with second-line anti-tuberculosis drugs should preferably
be based on the results of susceptibility testing. Accurate
and reliable laboratory drug susceptibility testing (DST)
data to SLDs are the basic requirement of the directly
observed treatment short course (DOTS)-Plus strategy, as
they will support clinical decision-making and help to
prevent the emergence of further drug resistance in
patients with MDR-TB (5,6). Furthermore, these data are
needed not only for individual case management, but also
for drug resistance surveillance (7,8). Susceptibility testing
of M. tuberculosis to SLDs is difficult, expensive, and not
well standardized. An alternative is, therefore, to perform
susceptibility testing of a sample of MDR strains in a region
and to base the treatment of MDR-TB on these results (6).
Most mycobacteriology laboratories do not perform
DST for SLDs and few studies are available showing the
pattern of the SLD resistance in Turkey. The aim of this
study was to analyze the resistance to second-line antituberculosis drugs of MDR strains of M. tuberculosis
isolated from the Aegean region of Turkey.
Materials and Methods
Strains
A total of 40 MDR M. tuberculosis isolates selected
from our strain collection were included in this study. All
of them had been isolated from individual patients in the
Aegean region of Turkey, between 01.01.2004 –
31.06.2007. All clinical strains had been identified initially
as M. tuberculosis using the NAP and standard
microbiological tests (niacin accumulation and nitrate
246
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reduction tests). Following identification, they had been
tested for susceptibility to the first-line anti-tuberculosis
drugs ethambutol, isoniazid, rifampin, and streptomycin
using the BACTEC 460 TB system (Becton Dickinson,
Sparks, MD, USA) by following the standard procedures
and as recommended by the manufacturer (9). The strains
had been stored at -70 ºC, and were freshly subcultured on
Lowenstein-Jensen (LJ) medium before use. M.
tuberculosis H37Rv (ATCC 27294; susceptible to all drugs
tested) was used as a strain for internal quality control.
Antimicrobial Agents
The drugs used were amikacin (AMI), capreomycin
(CAP), kanamycin (KM), ofloxacin (OFX), ethionamide
(ETH), and clofazimine (CFZ). All test drugs were
obtained in a chemically pure form (all from Sigma,
Taufkirchen, Germany, except for CFZ [Novartis
International Pharmaceutical Ltd., Ringaskiddy Co. Cork,
Ireland]).
AMI, CAP, and KM were dissolved in sterile distilled
water; OFX was dissolved in a 0.1 N NaOH solution.
Subsequent dilutions of these drugs were made in sterile
distilled water. ETH and CFZ were dissolved in dimethyl
sulfoxide and stored in the dark at room temperature.
Subsequent dilutions were made in the same solvent. Stock
solutions of each drug were made at 10,000 mg/ml
concentration. Except for CFZ and ETH, which are
considered self-sterilizing, all stock solutions were filtered
in a sterile manner with a 0.22-µm-pore-size
polycarbonate filter, and the first 20% of the initial filtrate
was discarded. All stock solutions except CFZ were stored
at -70 ºC in small aliquots. Frozen drug solutions were
thawed once and then discarded. CFZ was prepared daily
for each working batch.
Drug Susceptibility Testing (DST)
The DSTs were performed by the BACTEC 460 TB
radiometric method (Becton Dickinson Diagnostic
Instrument Systems, Sparks, MD, USA) following the
standard protocol (3,9). The final drug concentrations
used were 1.0 µg/ml for AMI; 1.25 µg/ml for CAP; 5.0
µg/ml for KM; 2.0 µg/ml for OFX; 1.25 µg/ml for ETH;
and 0.5 µg/ml for CFZ. Antimicrobials were always added
in 0.1 ml quantities to a BACTEC 12B vial to achieve the
desired concentrations. Susceptibility and resistance were
judged by comparison of the change in the growth index of
the control with that of the test drug as recommended.
This interpretation gave susceptibility results at the 1%
proportion basis.
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Results
A total of 40 MDR M. tuberculosis strains isolated
from patients with TB in the Aegean region of Turkey
were tested for susceptibility to the second-line antituberculosis drugs AMI, CAP, KM, OFX, ETH and CFZ.
Susceptibility patterns identified are presented in the
Table. Eighteen of the 44 (45%) strains were susceptible
to all SLDs tested. Twenty-two (55%) strains were
resistant at least to one of the SLDs tested. The results
showed that 37.5% of the 40 MDR-TB isolates were
resistant to ETH, 25% to CAP, 5% to AMI, 5% to KM,
5% to OFX, and 2.5% to CFZ. Mono-resistance to ETH,
CAP, OFX or KM was detected in 10 (25%), 4 (10%) 1

June 2008

(2.5%) and 1 (2.5%) strains, respectively. Monoresistance to CFZ or AMI was not detected. Resistance to
two drugs in different combinations was found in three
(7.5%) strains, resistance to three drugs was found in
two (5.0%) strains, and resistance to four drugs was
found in only one (2.5%) strain. One (2.5%) of MDR-TB
isolate cases was defined as extensively drug-resistant
tuberculosis (XDR-TB). Simultaneous resistance to all
SLDs tested was not observed. M. tuberculosis H37Rv
strain used for internal quality control was susceptible to
all SLDs tested.

Table. Resistance of the 40 MDR M. tuberculosis strains to second-line anti-tuberculosis drugs.
No of strains

%

SUSCEPTIBLE TO ALL DRUGS

18

45.0

ANY RESISTANCE

22

55.0

- ethionamide (ETH)

15

37.5

- capreomycin (CAP)

10

25.0

- amikacin (AMI)

2

5.0

- kanamycin (KM)

2

5.0

- ofloxacin (OFX)

2

5.0

- clofazimine (CFZ)

1

2.5

MONO-RESISTANCE

16

40.0

- ethionamide (ETH)

10

25.0

- capreomycin (CAP)

4

10.0

- amikacin (AMI)

0

0.0

- kanamycin (KM)

1

2.5

- ofloxacin (OFX)

1

2.5

- clofazimine (CFZ)

0

0.0

OTHER PATTERNS

6

15.0

- CAP + ETH

2

5.0

- CAP + CFZ

1

2.5

- CAP + ETH + OFX*

1

2.5

- CAP + ETH + AMI

1

2.5

- CAP + ETH + AMI + KM

1

2.5

2 drugs

3

7.5

3 drugs

2

5.0

4 drugs

1

2.5

5 drugs

0

0.0

all drugs

0

0.0

NUMBER OF DRUGS RESISTANT TO:

* This is a pattern of extensively drug-resistant tuberculosis (XDR-TB).
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Discussion
Despite recent progress in global control efforts, TB
remains a major public health burden in most developing
countries, and the total number of new TB cases is still
rising slowly. There were an estimated 8.8 million new
TB cases in 2005, with 7.4 million in Asia and subSaharan Africa (10). Instead of being eradicated, drugresistant strains have evolved and have been documented
in every country surveyed. Once a strain of M.
tuberculosis develops resistance to isoniazid and rifampin,
it is defined as MDR-TB. According to the World Health
Organization (WHO) reports, MDR-TB is a slowly
increasing health problem (1). The incidence of MDR-TB
in the Aegean region of Turkey was found to be 6.8%
(11), while the worldwide mean of the incidence of MDRTB is 1.7% (1).

Turk J Med Sci

recommended by Pfyffer et al. (3) and accepted
internationally (19) were used to perform susceptibility
testing with the SLDs.
In the present study, we analyzed resistance to AMI,
CAP, KM, OFX, ETH, and CFZ of MDR M. tuberculosis
strains isolated from patients with TB in the Aegean
region of Turkey. At 37.5%, ETH resistance was the
highest among all SLDs tested. This result is not
surprising, since cross-resistance between ETH, a
derivative of isonicotinic acid, and isoniazid can occur
(20). This may explain why the rate of resistance to ETH
is high in this study. However, the fact that all tested
isolates were resistant to isoniazid but only 37.5% were
resistant to ETH might suggest that the mutations
leading to drug resistance are located in different regions
of the genome (21,22).

The treatment of MDR-TB becomes difficult since
SLDs must be used, which are less potent and not as well
tolerated as first-line agents. While this is often done
without testing the susceptibility of MDR strains to SLDs,
susceptibility testing is important in order to determine
an effective treatment regimen and to avoid further
development of resistance in patients with MDR-TB
(5,6,12). Second-line treatment can be individualized,
based on in-vitro drug resistance, or standardized. Even
with standardized protocols, there is a need for accurate
resistance data for SLDs after the preliminary drug
resistance surveys are completed. Although individualized
treatment is probably best, the need for reliable but
costly laboratory facilities for DST means that
standardized SLD treatment has been advocated for use
in middle- and low-income countries. The latter strategy
requires detailed knowledge of likely drug-resistance
patterns, particularly for MDR-TB strains, which requires
recent regional surveys or surveillance of resistance (13).

The rate of resistance to ETH in MDR-TB cases was
also found to be high by different studies from Turkey
(56.2%, 38.6%, 22.0%, 32.8%) (14-17) and from
other regions of the world (48.6% in Argentina, 21.2%
in Thailand) (21,23), while all MDR-TB cases in Ethiopia
(24) were sensitive to ETH. Toungoussova et al. (6)
found very high rate of resistance to ETH in MDR-TB in
Russia (92.2%) and suggested that ETH was not readily
available during the economic crisis in Russia and this
might have created the necessary conditions for the
emergence of resistance to ETH.

There are few articles examining the resistance to
SLDs in Turkey. They show that the rate of susceptibility
to SLDs varies in different parts of the country. However,
there are differences in methods employed for DST,
including the critical concentrations of drugs and critical
proportions of resistance used in these studies (14-17).
The quality of susceptibility testing results is clearly an
important issue. DST for both primary and secondary
anti-TB drugs with the broth-based radiometric BACTEC
460 TB system is well established and is considered the
“gold standard” (4,18). In the present study, BACTEC
460 TB system and the drug concentrations

AMI and KM are aminoglycoside antibiotics that bind
to 16S rRNA as their target in a small ribosomal subunit
and subsequently inhibit protein synthesis (23). We
selected both AMI and KM for testing. Resistance to AMI
or KM was found to be 5.0%. One of two strains
resistant to KM was also resistant to AMI, ETH and CAP,
while the other strain was resistant only to KM. Both
strains resistant to AMI were also resistant to ETH and
CAP. M. tuberculosis can develop resistance to KM as a
result of cross-resistance between the aminoglycosides,
but the binding site of each of the aminoglycosides may
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We tested OFX as a representative of the
fluoroquinolones. Of 40 MDR-TB strains, only 2 (5.0%)
were resistant to OFX. One of strains resistant to the OFX
was also resistant to ETH and CAP. Similarly, in most
previous studies from Turkey and other countries, OFX
was found to be one of the most active drugs against
MDR-TB (1.3% in Russia, 9.1% in Thailand, 4.0% in
Turkey) (6,23,16).
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be different; therefore, the ribosomal mutations that
mediate resistance to aminoglycosides are likely to be
drug-specific (25).

CAP. Similar rates for CFZ were reported from different
parts of the world: 93.5% from Argentina (21), 100%
from Ethiopia (24) and 97.1% from Russia (13).

CAP, the basic peptide antimicrobial agent with a
mechanism of action similar to that of the
aminoglycosides, is sometimes used in combination
therapy for the treatment of MDR-TB (19,20). In the
present study, the proportion of strains resistant to CAP
(25%) was higher than resistance to the other
aminoglycosides, KM and AMI. Only two of 10 strains
resistant to CAP were also resistant to AMI. Di Perri et al.
(25) reported that CAP-resistant strains are not usually
resistant to AMI.

Extensively drug-resistant tuberculosis (XDR-TB) is
defined as resistance to at least rifampin and isoniazid
from the first-line anti-TB drugs (the definition of MDRTB) in addition to resistance to any fluoroquinolone, and
to at least one of three injectable second-line anti-TB
drugs used in TB treatment (CAP, KM, and AMI) (26). In
the present study, one (2.5%) of the MDR-TB cases met
the criteria for XDR-TB. This isolate was resistant to CAP,
OFX and ETH.

In most of the previous studies, a high rate of
susceptibility to aminoglycosides among MDR-TB cases
has been reported (13-16,23). However, Toungoussova
et al. (6) from Russia and Morcillo et al. (21) from
Argentina reported higher rates of resistance to KM
(41.6% and 28.3%), which might be partially explained
by the administration of these drugs or analogues to
previously treated patients as monotherapy (6).
CFZ is an active drug against MDR-TB in vitro and in
murine model, but no clinical data on its use for treating
MDR-TB are currently available (12,19,25). In the
present study, CFZ was active against the MDR strains of
M. tuberculosis in nearly all cases (97.5%); only one
isolate was resistant to CFZ and it was also resistant to

In conclusion, according to the present study,
aminoglycosides (KM and AMI) and OFX were rather
active drugs against MDR-TB and they can be used in the
treatment regimen in our region without any problems.
ETH and CAP, however, were effective in 62.5% and
75.0% of the cases, respectively. Alternative drugs are
necessary for patients that harbor strains resistant to
ETH and CAP. In addition, XDR-TB does not yet seem to
be a serious problem in the Aegean region of Turkey.
These results may be of use in our region to establish
a standardized regimen for the treatment of patients with
MDR-TB until reliable results of susceptibility testing for
SLDs are available, after which individualized treatments
with SLDs will be feasible.
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